Review of TA181: Pemetrexed for the first-line treatment of non-small-cell lung cancer, TA190: Pemetrexed for the maintenance treatment of non-small-cell lung cancer, TA192: Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer, TA227: Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer, and TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer

Proposal to move the existing guidance to the static list

The planned date for review of the above pieces of guidance was scheduled to be after the publication of an independent Health Technology Assessment (HTA) report on ‘First-line therapy for adult patients with non-small cell lung cancer’ that was being compiled by the Liverpool Review and Implementation Group (LRiG), Liverpool University.

Now that this report has published, NICE has looked again at whether there is sufficient evidence for the Appraisal Committee to be asked to undertake a full review appraisal.

Having assessed the newly available evidence, we believe that it would not lead to a change in the existing recommendations.  Consequently we propose that TA181, TA190, TA192, TA227 and TA258 should all move to the static list of technology appraisals.

Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which will help us decide the best way to update this guidance.  Please see appendix A for a full list of the organisations we have contacted

October 2014

Attachments

Appendix A – matrix of stakeholders

Appendix B – proposal paper presented to the Institute’s Guidance Executive